Adjuvant Ribociclib for Early-Stage Hormone Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant ribociclib in patients with early-stage hormone receptor-positive breast cancer.